A new molecular approach to assess the occurrence of Sarcocystis spp. in cattle and products thereof: preliminary data

The genus Sarcocystis consists of more than 200 species. Those protozoa are characterised by a biological cycle composed by two obligatory hosts, definitive and intermediate. Apart from being possibly pathogenic for the intermediate host, a number of authors consider the intestinal sarcocystosis a minor zoonotic disease. Humans, in fact, can act as definitive host for two sarcosporidian species, S. suihominis e S. hominis, being infected through the consumption of raw or undercooked pig and bovine meat, respectively. Other two species could parasitise cattle: S. cruzi and S. hirsuta, having canids and felids as definitive hosts, respectively. The three species differentiate from each other in dimensions and cystic wall morphology, this latter being the basis for taxonomical studies. In 2010, the European Food Safety Authority (EFSA) highlighted the absence of reliable methods for epidemiological studies on the presence of Sarcocystis spp. in animals and products thereof. On this basis, the present study has been developed a new molecular method for the identification of Sarcocystis in bovine meat. For the development of the polymerase chain reaction (PCR) protocol, a set of samples of bovine meat from cattle (N=15), slaughtered at the didactic abattoir at the Veterinary Faculty of Turin University, has been collected, sequenced and used as reference samples during the study. A second set of samples (N=29), gathered from the same abattoir (N=12) and from abattoirs of Piedmont region (N=17), has been used for applicability tests. The overall positive rate for Sarcocystis spp. in our samples has been 91% (40/44), with S. cruzi representing the species with higher rates (68%), followed by S. hominis (43%) and S. hirsuta (2%). Based on the results of specificity and applicability tests performed in this study, the newly developed protocol proved to be reliable and suitable for epidemiologic purposes

Development and validation of an indirect ELISA as a confirmatory test for surveillance of infectious bovine rhinotracheitis in vaccinated herds

BACKGROUND: Bovine herpesvirus 1 (BoHV1) is a member of the viral subfamily of Alphaherpesvirinae that infects various species, including cattle, sheep, and goats. The virus causes infectious bovine rhinotracheitis (IBR), which is included in a European list of diseases that may require control and eradication programs. The lack of confirmatory tests affects the validity of diagnostic tools, especially those used for vaccinated herds. In this study, we report the development and validation of an indirect enzyme-linked immunosorbent assay (ELISA) based on BoHV1 glycoprotein E, which was expressed as a secreted recombinant antigen in a mammalian cell system. The performance of the new rec-gE ELISA was compared with that of commercially available indirect and/or blocking ELISAs. RESULTS: The sample set included blood sera from animals from IBR-positive farms, IBR-free farms, and marker-vaccinated farms. The indirect ELISA proposed in this study is based on antibody reactivity against BoHV1 gE, and showed high sensitivity and specificity (98.41 and 99.76 %, respectively). CONCLUSIONS: The ELISA performed well, in terms of both its diagnostic sensitivity and specificity, and as a confirmatory methodology, and therefore should improve the diagnostic protocols used for IBR surveillance

Colorectal Cancer Stage at Diagnosis Before vs During the COVID-19 Pandemic in Italy

IMPORTANCE Delays in screening programs and the reluctance of patients to seek medical attention because of the outbreak of SARS-CoV-2 could be associated with the risk of more advanced colorectal cancers at diagnosis. OBJECTIVE To evaluate whether the SARS-CoV-2 pandemic was associated with more advanced oncologic stage and change in clinical presentation for patients with colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS This retrospective, multicenter cohort study included all 17 938 adult patients who underwent surgery for colorectal cancer from March 1, 2020, to December 31, 2021 (pandemic period), and from January 1, 2018, to February 29, 2020 (prepandemic period), in 81 participating centers in Italy, including tertiary centers and community hospitals. Follow-up was 30 days from surgery. EXPOSURES Any type of surgical procedure for colorectal cancer, including explorative surgery, palliative procedures, and atypical or segmental resections. MAIN OUTCOMES AND MEASURES The primary outcome was advanced stage of colorectal cancer at diagnosis. Secondary outcomes were distant metastasis, T4 stage, aggressive biology (defined as cancer with at least 1 of the following characteristics: signet ring cells, mucinous tumor, budding, lymphovascular invasion, perineural invasion, and lymphangitis), stenotic lesion, emergency surgery, and palliative surgery. The independent association between the pandemic period and the outcomes was assessed using multivariate random-effects logistic regression, with hospital as the cluster variable. RESULTS A total of 17 938 patients (10 007 men [55.8%]; mean [SD] age, 70.6 [12.2] years) underwent surgery for colorectal cancer: 7796 (43.5%) during the pandemic period and 10 142 (56.5%) during the prepandemic period. Logistic regression indicated that the pandemic period was significantly associated with an increased rate of advanced-stage colorectal cancer (odds ratio [OR], 1.07; 95%CI, 1.01-1.13; P = .03), aggressive biology (OR, 1.32; 95%CI, 1.15-1.53; P < .001), and stenotic lesions (OR, 1.15; 95%CI, 1.01-1.31; P = .03). CONCLUSIONS AND RELEVANCE This cohort study suggests a significant association between the SARS-CoV-2 pandemic and the risk of a more advanced oncologic stage at diagnosis among patients undergoing surgery for colorectal cancer and might indicate a potential reduction of survival for these patients